Abstract showing activity in MDS of BerGenBio’s first-in-class AXL inhibitor, BGB324, accepted for presentation at ASCO Annual Meeting 2017
Bergen, Norway, May, 19 2017 – Leading oncology biopharmaceutical company BerGenBio ASA, announces that its first-in-class small molecule Axl inhibitor BGB324 will be featured in a poster presentation at the upcoming 2017 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL from June 2-6, 2017. The presentation will focus on pre-clinical as well as clinical activity of BGB324 in high-risk Myeloid Dysplastic Syndrome (MDS).The details of the poster presentation are as follows: Blockade of Axl with the small molecule inhibitor BGB324 shows activity in vitro and in